JPT Peptide Technologies Launches The Human Proteome Peptide Catalog
JPT Peptide Technologies (JPT) announces the launch of The Human Proteome Peptide Catalog, the first and most comprehensive online resource for validated reference peptides in mass-spectrometry based proteomics.
The new repository provides fast access to >400.000 light & heavy proteotypic peptides covering essentially all proteins of the human body. Currently, a total of 19.840 proteins is matched by the peptide collection and confirmed by more than 10.000.000 validated spectra available through the database ProteomicsDB.
Holger Wenschuh, Managing Director of JPT, states: “Together with our partners within the ProteomeTools Project we have worked for several years towards the goal of translating the human proteome information into reagents and online tools to decipher the complexity of the human organism on the functional level”, adding: “We are extremely excited to make this repository available to the broad life science community enabling a completely new dimension of research and development using mass-spectrometry based proteomics approaches.”
The Human Proteome Peptide Catalog is an interactive knowledge, spectra and peptide resource that will be continuously expanded with the support of JPT’s partners at the Technical University of Munich to also address a broad level of post-translational modifications, splice-variants, mutations and more.
JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG, is an DIN ISO 9001:2015 certified research and development partner and innovative service provider for peptide related projects in immunotherapy, proteomics and drug discovery. JPT’s key technologies SPOTTM – for ultra-high-throughput peptide synthesis and screening, PepStarTM – for high-content peptide microarrays, PepTrackTM - for flexible peptide library assembly, PepMixTM – for antigen specific T-cell stimulation using peptide pools, and SpikeTidesTM/SpikeMixTM – for protein biomarker discovery and quantification accelerate research and development in areas such as cell and immunotherapy, vaccine development, biomarker discovery, peptide lead identification and optimization, and proteomics. For more information, please visit www.jpt.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005159/en/
Contact information
JPT Peptide Technologies
Dr. Holger Wenschuh
Managing
Director
T +49-30-6392-5500
X +49-30-6392-5501
peptide@jpt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ravio raises $12m Series A to modernise compensation data for global workforces8.5.2025 10:00:00 EEST | Press release
Ravio has raised a $12m Series A funding round led by Spark Capital (US) with participation from Blackbird (Australia) and Cherry Ventures (Europe) to modernise how companies manage compensation with real-time market data and decision making tools. Ravio counts leading consumer brands like Just Eat Takeaway and Octopus Energy among its customers, alongside fintech leaders such as Wise, Adyen, and Mollie. Popular tech names like Zoopla and Skyscanner have also chosen Ravio to set their compensation strategies. The compensation data gap Despite representing 70% of operating costs, most companies make these important decisions using patchy data that's 12-18 months old. This outdated approach creates significant issues: Talent leaves when underpaid compared to current market rates Companies overspend on some roles while struggling to attract talent in others Pay inequities develop as new hires and existing staff operate from different reference points "The idea for Ravio was born from runn
Celonis Recognized as a Leader for Third Consecutive Year in 2025 Gartner® Magic Quadrant™ for Process Mining Platforms8.5.2025 10:00:00 EEST | Press release
Celonis, the global leader in Process Mining and Process Intelligence, today announced that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the third time. Celonis was placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and furthest on the Completeness of Vision axis once again. “We are honored to be named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the third year in a row,” said Alex Rinke, co-CEO and co-founder of Celonis. “We believe this recognition is a testament to our pioneering product innovation, our system-agnostic Process Intelligence platform, and our impressive global partner network. This recognition wouldn’t have been possible without the dedication and commitment of our customers, partners and Celonauts. Looking ahead, what excites me most is the huge potential for Celonis to enable our customers to maximize the ROI from their AI investments.” “Celonis gives us a s
Vista Equity Partners Launches VistaOne to Expand Access to Private Software Investments8.5.2025 10:00:00 EEST | Press release
Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the launch of VistaOne (Lux) (“VistaOne” or the “Fund”), an open-ended investment vehicle that provides eligible non-US individual investors access to Vista’s private equity platform in a single, scaled solution. The software sector has a projected 2027 total addressable market of $59 trillion and a growth rate of approximately 17%, making it the largest and fastest growing in the global economy.1 Yet approximately 96% of software companies are privately held and therefore inaccessible to most individual investors.2 VistaOne is one of the first software-specific evergreen private equity funds available to the private wealth market. Founded in 2000, Vista is an operationally focused investor that pioneered a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Enterprise software touches almost ev
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress8.5.2025 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year. FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE® generic impact, continued efficiency savings and investment in R&D and launch preparation for Takeda’s late-stage pipeline. Takeda chief executive officer, Christophe Weber, commented: “Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Laun
AB InBev Reports First Quarter 2025 Results8.5.2025 08:03:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3% to 13 628 million USD, impacted by unfavorable currency translation. 4.4% increase in combined revenues of our megabrands, led by Corona, which g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom